Samieh Asadia
Tehran University, Iran
Title: Radioimmunotherapy for Hepatocellular Carcinoma treatment
Biography:
I am PhD candidate of Molecular Medicine. My field of study is liver and gastrointestinal. These days using Radioneacluide therapy for treatment of cancers are common, so based on my interest I'm working on my PhD thesis at Royan institute as: "Evaluation of 188Re-HDD Lipiodol Hydrogel as a new radioisotope for treatment of hepatocellular carcinoma". Assessments include of In-Vitro and In-Vivo evaluations. I also graduated from Tehran University of Medical Sciences. My educational and practice-based background has trained me in Medical Sciences. Many of my courses were related to new diagnostic methods and microscopic practices in medical laboratory diagnosis.
Abstract:
Liver cancer is responsible for the sixth common diagnosed cancer worldwide and forth causes of cancer death. Based on stages of HCC at the time of diagnosis, therapeutic options are limited and mostly end with treatment failure, recurrence, or poor prognosis. Radio immunotherapy (RIT) illustrates a selective internal radiation therapy by means of beta or alpha emitting radioisotopes conjugated with tumor-specific monoclonal antibodies, fragments, or peptides. Selected radiolabeled monoclonal antibodies can present high therapeutic radiation dose to cancerous cells while decreasing the exposure of healthy tissues by specific interaction to cancer-associated antigens on surface of tumor cells. Developments in cancer immunotherapy such as blockade of immunologic checkpoint has changed the landscape of cancer therapy, and clinical efficacy of several classes of immunotherapy has been tested in clinical trials. Taking into the account of the immune inhibitor agents operating in the liver tumor microenvironment—combination therapies of different approaches might be influenced for achieving the best clinical results